LY 3303560

Drug Profile

LY 3303560

Alternative Names: LY3303560

Latest Information Update: 14 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 31 Jan 2017 Phase-I clinical trials in Alzheimer's disease in Japan, United Kingdom (IV) after January 2017 (NCT03019536)
  • 31 Jan 2017 Phase-I clinical trials in Alzheimer's disease in Japan, United Kingdom (SC) after January 2017 (NCT03019536)
  • 13 Jan 2017 Eli Lilly initiates a phase I trial in Alzheimer's disease in USA (NCT03019536)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top